Vincerx Inc (VINC) Actualités

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943

PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical...

Form 8-K - Current report

Form 8-K - Current report

Vincerx Pharma Reports Third Quarter 2024 Financial Results

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123...

Form PRE 14A - Other preliminary proxy statements

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1...

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC TO-I - Tender offer statement by Issuer